Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $4.37 billion. The enterprise value is $3.48 billion.
| Market Cap | 4.37B |
| Enterprise Value | 3.48B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 73.27 million shares outstanding. The number of shares has increased by 26.53% in one year.
| Current Share Class | 73.27M |
| Shares Outstanding | 73.27M |
| Shares Change (YoY) | +26.53% |
| Shares Change (QoQ) | +5.37% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 96.94% |
| Float | 60.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.88 |
| P/TBV Ratio | 4.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 64.07, with a Debt / Equity ratio of 0.00.
| Current Ratio | 64.07 |
| Quick Ratio | 63.21 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.31% and return on invested capital (ROIC) is -11.22%.
| Return on Equity (ROE) | -15.31% |
| Return on Assets (ROA) | -11.00% |
| Return on Invested Capital (ROIC) | -11.22% |
| Return on Capital Employed (ROCE) | -13.88% |
| Weighted Average Cost of Capital (WACC) | 5.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 67 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +185.54% in the last 52 weeks. The beta is 0.25, so ELVN's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +185.54% |
| 50-Day Moving Average | 55.46 |
| 200-Day Moving Average | 37.45 |
| Relative Strength Index (RSI) | 57.89 |
| Average Volume (20 Days) | 788,950 |
Short Selling Information
The latest short interest is 8.26 million, so 11.27% of the outstanding shares have been sold short.
| Short Interest | 8.26M |
| Short Previous Month | 8.15M |
| Short % of Shares Out | 11.27% |
| Short % of Float | 13.65% |
| Short Ratio (days to cover) | 8.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -124.41M |
| Pretax Income | -105.93M |
| Net Income | -105.93M |
| EBITDA | -124.28M |
| EBIT | -124.41M |
| Earnings Per Share (EPS) | -$1.67 |
Balance Sheet
The company has $895.16 million in cash and $1.51 million in debt, with a net cash position of $893.65 million or $12.20 per share.
| Cash & Cash Equivalents | 895.16M |
| Total Debt | 1.51M |
| Net Cash | 893.65M |
| Net Cash Per Share | $12.20 |
| Equity (Book Value) | 895.15M |
| Book Value Per Share | 12.22 |
| Working Capital | 893.18M |
Cash Flow
In the last 12 months, operating cash flow was -$66.94 million and capital expenditures -$98,000, giving a free cash flow of -$67.04 million.
| Operating Cash Flow | -66.94M |
| Capital Expenditures | -98,000 |
| Depreciation & Amortization | 129,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -67.04M |
| FCF Per Share | -$0.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.53% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.42% |
| FCF Yield | -1.53% |
Analyst Forecast
The average price target for ELVN is $73.90, which is 23.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $73.90 |
| Price Target Difference | 23.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |